share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股SEC公告 ·  07/29 19:52
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on May 6, 2024. As part of a larger 12-month share repurchase initiative with a budget of up to DKK 20 billion that started on February 6, 2024, the company has been buying back B shares. From May 7, 2024, to August 5, 2024, Novo Nordisk is set to repurchase B shares worth up to DKK 2.2 billion. The latest transactions, reported on July 29, 2024, show that since the last announcement on July 22, 2024, the company has acquired an additional 201,500 B shares, spending approximately DKK 181,490,215. This brings the total repurchased under the program to 2,086,287 B shares at a cost of DKK 1,980,536,332. Novo Nordisk now holds 12,186,327 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on May 6, 2024. As part of a larger 12-month share repurchase initiative with a budget of up to DKK 20 billion that started on February 6, 2024, the company has been buying back B shares. From May 7, 2024, to August 5, 2024, Novo Nordisk is set to repurchase B shares worth up to DKK 2.2 billion. The latest transactions, reported on July 29, 2024, show that since the last announcement on July 22, 2024, the company has acquired an additional 201,500 B shares, spending approximately DKK 181,490,215. This brings the total repurchased under the program to 2,086,287 B shares at a cost of DKK 1,980,536,332. Novo Nordisk now holds 12,186,327 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
全球領先的保健公司諾和諾德正在積極執行其股票回購計劃，該計劃於2024年5月6日宣佈。作爲一項擁有高達200億丹麥克朗預算、爲期12個月的大規模股票回購計劃的一部分，該公司一直在回購B股。從2024年5月7日至2024年8月5日，諾和諾德將回購價值高達22億丹麥克朗的B股。最新交易數據於2024年7月29日披露，自2024年7月22日上次公告以來，該公司額外收購了2015000億股，花費約181,490,215丹麥克朗。這將該計劃下回購總數提高至20862870億股，平均成本爲1,980,536,332丹麥克朗。諾和諾德現持有121863270億股作爲庫存股份，該份額佔股本的0.3％。該公司的股票在納斯達克哥本哈根和紐約證券交易所上市。
全球領先的保健公司諾和諾德正在積極執行其股票回購計劃，該計劃於2024年5月6日宣佈。作爲一項擁有高達200億丹麥克朗預算、爲期12個月的大規模股票回購計劃的一部分，該公司一直在回購B股。從2024年5月7日至2024年8月5日，諾和諾德將回購價值高達22億丹麥克朗的B股。最新交易數據於2024年7月29日披露，自2024年7月22日上次公告以來，該公司額外收購了2015000億股，花費約181,490,215丹麥克朗。這將該計劃下回購總數提高至20862870億股，平均成本爲1,980,536,332丹麥克朗。諾和諾德現持有121863270億股作爲庫存股份，該份額佔股本的0.3％。該公司的股票在納斯達克哥本哈根和紐約證券交易所上市。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。